Strategic Partnership between Kilani Groupe and Sanofi
The Kilani Groupe has entered into a strategic partnership with Sanofi to ensure the continuity of the laboratory's activities in Tunisia. This agreement provides for the local manufacture of medicines as well as the management of medical information and scientific activities.
Partnership Objectives
This partnership is part of a strategic evolution of Sanofi's activities in the Tunisian market. It aims to guarantee patients' sustainable access to quality treatments and strengthen the role of local players in the pharmaceutical industry.
Local Manufacturing and Medical Information
Within this framework, the Teriak subsidiary will be responsible for the local manufacture of a portfolio of Sanofi medicines. This mission will enable the strengthening of national production and contribute to improving the availability of treatments.
Medical Information and Scientific Promotion
The MEDICIS S.A.R.L company will ensure medical information and exchanges with health authorities. It will also be responsible for scientific promotion among healthcare professionals. This role aims to guarantee the continuity of scientific and medical activities.
Key Benefits
The partnership between Kilani Groupe and Sanofi is expected to have a positive impact on the Tunisian pharmaceutical industry, ensuring the availability of quality medicines and promoting local production. This collaboration will also strengthen the role of local actors in the industry, contributing to the country's healthcare system.
